Seattle Genetics plans to file breast cancer drug tucatinib

Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in a heavily pre-treated group of patients with advanced disease.

AZ/Daiichi's possible breast cancer blockbuster gets fast US...

The FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan, setting up a possible launch as early as Q2 next year.

NICE says 'no' to regular NHS funding for Roche's Tecentriq ...

NICE has said Roche's Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a treatment for metastastic triple negative breast cancer (TNBC), saying that it

Merck & Co hopes for foothold in early TNBC after Keytruda t...

Merck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold in the tough-to-treat triple negative breast cancer (TNBC) indication, and potentiall

Tecentriq beats rivals to EU breast cancer market

Study resurrects Merck’s hopes for Keytruda in breast cancer